seed
Stage
2
Investors
About
Gefjon Pharma develops a genetically modified bacterial strain-based OMV platform for cost-effective production of vaccines and biologics, with a lead product of an aerosol-administered broad-spectrum E. coli vaccine for poultry.
Explore Gefjon Pharma's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.